Scopolamine (injection): Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
|drugClass=[[anticholinergic]] agent | |drugClass=[[anticholinergic]] agent | ||
|indicationType=treatment | |indicationType=treatment | ||
|indication=central nervous system as a sedative and tranquilizing depressant and it is an effective antiemetic | |indication=central nervous system as a [[sedative]] and [[tranquilizing]] depressant and it is an effective [[antiemetic]] | ||
|adverseReactions=[[dry mouth]], [[dizziness]], [[somnolence]], [[urinary retention]], [[agitation]], [[visual impairment]], [[confusion]], [[mydriasis]] and [[pharyngitis]] | |adverseReactions=[[dry mouth]], [[dizziness]], [[somnolence]], [[urinary retention]], [[agitation]], [[visual impairment]], [[confusion]], [[mydriasis]] and [[pharyngitis]] | ||
| Line 19: | Line 19: | ||
<!--FDA-Labeled Indications and Dosage (Adult)--> | <!--FDA-Labeled Indications and Dosage (Adult)--> | ||
|fdaLIADAdult=*Scopolamine Hydrobromide Injection, USP is indicated as a sedative and tranquilizing depressant to the central nervous system. In its peripheral actions, scopolamine differs from atropine in that it is a stronger blocking agent for the iris, ciliary body and salivary, bronchial and sweat glands but is weaker in its action on the heart (in which it is incapable of exerting actions in tolerated doses), the intestinal tract and bronchial musculature. | |fdaLIADAdult=*Scopolamine Hydrobromide Injection, USP is indicated as a sedative and tranquilizing depressant to the central nervous system. In its peripheral actions, scopolamine differs from [[atropine]] in that it is a stronger blocking agent for the iris, [[ciliary body]] and salivary, bronchial and sweat glands but is weaker in its action on the heart (in which it is incapable of exerting actions in tolerated doses), the intestinal tract and bronchial musculature. | ||
*In addition to the usual uses for antimuscarinic drugs, scopolamine is employed for its central depressant actions as a sedative. Frequently it is given as a preanesthetic medicament for both its sedative-tranquilizing and antisecretory actions. It is an effective antiemetic. It is used in maniacal states, in delirium tremens and in obstetrics. As a mydriatic and cycloplegic, it has a somewhat shorter duration (3 to 7 days) and intraocular pressure is affected less markedly than with atropine. | *In addition to the usual uses for [[antimuscarinic]] drugs, scopolamine is employed for its central depressant actions as a sedative. Frequently it is given as a [[preanesthetic]] medicament for both its [[sedative]]-[[tranquilizing]] and [[antisecretory actions]]. It is an effective [[antiemetic]]. It is used in maniacal states, in [[delirium tremens]] and in [[obstetrics]]. As a [[mydriatic]] and [[cycloplegic]], it has a somewhat shorter duration (3 to 7 days) and [[intraocular pressure]] is affected less markedly than with [[atropine]]. | ||
=====Dosing Information===== | =====Dosing Information===== | ||
*For obstetric amnesia or preoperative sedation, 0.32 to 0.65 mg (320 to 650 mcg). | *For obstetric [[amnesia]] or preoperative sedation, 0.32 to 0.65 mg (320 to 650 mcg). | ||
*For sedation or tranquilization, 0.6 mg (600 mcg) 3 or 4 times a day. | *For [[sedation]] or [[tranquilization]], 0.6 mg (600 mcg) 3 or 4 times a day. | ||
*Subcutaneous, as an antiemetic, 0.6 to 1 mg. | *Subcutaneous, as an [[antiemetic]], 0.6 to 1 mg. | ||
: [[File:{{PAGENAME}}03.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | : [[File:{{PAGENAME}}03.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | ||
*Belladonna alkaloids provide a therapeutic effect in about 1 or 2 hours with a duration of about 4 hours. | *[[Belladonna alkaloids]] provide a therapeutic effect in about 1 or 2 hours with a duration of about 4 hours. | ||
*Geriatric and debilitated patients may respond to the usual doses with excitement, agitation, drowsiness or confusion; lower doses may be required in such patients. | *Geriatric and debilitated patients may respond to the usual doses with excitement, [[agitation]], [[drowsiness]] or [[confusion]]; lower doses may be required in such patients. | ||
*Close supervision is recommended for infants, blondes, mongoloids and children with spastic paralysis or brain damage, since an increased responsiveness to belladonna alkaloids has been reported in these patients and dosage adjustments are often required. | *Close supervision is recommended for infants, blondes, mongoloids and children with [[spastic paralysis]] or brain damage, since an increased responsiveness to [[belladonna alkaloids]] has been reported in these patients and dosage adjustments are often required. | ||
*Administration of belladonna alkaloids and barbiturates 30 to 60 minutes before meals is recommended to maximize absorption and, when issued for reducing stomach acid formation, to allow its effect to coincide better with antacid administration following the meal. | *Administration of [[belladonna alkaloids]] and [[barbiturates]] 30 to 60 minutes before meals is recommended to maximize absorption and, when issued for reducing stomach acid formation, to allow its effect to coincide better with [[antacid]] administration following the meal. | ||
*Parenteral drug products should be inspected visually for particulate matter prior to administration, whenever solution and container permit. | *Parenteral drug products should be inspected visually for particulate matter prior to administration, whenever solution and container permit. | ||
| Line 59: | Line 59: | ||
<!--Contraindications--> | <!--Contraindications--> | ||
|contraindications=*Scopolamine hydrobromide is contraindicated in patients with narrow-angle glaucoma, since administration of the drug could raise the intraocular pressure to dangerous levels. However, this will not happen for side-angle glaucoma patients. Repeated administration of scopolamine to a patient with chronic lung disease is considered to be potentially hazardous. Patients hypersensitive to belladonna or to barbiturates may be hypersensitive to scopolamine hydrobromide. | |contraindications=*Scopolamine hydrobromide is contraindicated in patients with narrow-angle glaucoma, since administration of the drug could raise the [[intraocular pressure]] to dangerous levels. However, this will not happen for side-angle [[glaucoma]] patients. Repeated administration of scopolamine to a patient with chronic lung disease is considered to be potentially hazardous. Patients hypersensitive to belladonna or to barbiturates may be hypersensitive to scopolamine hydrobromide. | ||
<!--Warnings--> | <!--Warnings--> | ||
|warnings=*Addiction does not occur, although vomiting, malaise, sweating and salivation have been reported in patients with parkinsonism upon sudden withdrawal of large doses of scopolamine. Scopolamine is one of the most important drugs of the belladonna group from the standpoint of poisoning; infants and young children are especially susceptible to the belladonna alkaloids. Scopolamine is usually stated more toxic than atropine. Idiosyncrasy is more common with scopolamine than with atropine and ordinary therapeutic doses sometimes cause alarming reactions. | |warnings=*Addiction does not occur, although vomiting, malaise, sweating and salivation have been reported in patients with [[parkinsonism]] upon sudden withdrawal of large doses of scopolamine. Scopolamine is one of the most important drugs of the belladonna group from the standpoint of poisoning; infants and young children are especially susceptible to the [[belladonna alkaloids]]. Scopolamine is usually stated more toxic than atropine. Idiosyncrasy is more common with scopolamine than with atropine and ordinary therapeutic doses sometimes cause alarming reactions. | ||
*FOR TOPICAL OPHTHALMIC USE ONLY - NOT FOR INJECTION. | *FOR TOPICAL OPHTHALMIC USE ONLY - NOT FOR INJECTION. | ||
| Line 67: | Line 67: | ||
====Precautions==== | ====Precautions==== | ||
* If there is mydriasis and photophobia, dark glasses should be worn. Appropriate dosage precautions must be taken with infants, children, persons with mongolism, brain damage, spasticity, or light irides. Elevated intraocular pressure, urinary difficulty and retention and constipation are more probable in elderly persons. Men with prostatic hypertrophy should especially be monitored for urinary function. Because of the tachycardic effects of the drugs, care must be exercised when tachycardia, other tachyarrhythmias, coronary heart disease, congestive heart disease or hyperthyroidism preexist. Persons with hypertension may experience both exaggerated orthostatic hypotension and tachycardia. Similarly, autonomic neuropathy requires caution. Persons with a history of allergies or bronchial asthma will show a higher than normal incidence of hypersensitivity reactions. | * If there is [[mydriasis]] and [[photophobia]], dark glasses should be worn. Appropriate dosage precautions must be taken with infants, children, persons with mongolism, brain damage, [[spasticity]], or light irides. Elevated intraocular pressure, urinary difficulty and retention and [[constipation]] are more probable in elderly persons. Men with [[prostatic hypertrophy]] should especially be monitored for urinary function. Because of the [[tachycardic]] effects of the drugs, care must be exercised when [[tachycardia]], other [[tachyarrhythmias]], [[coronary heart disease]], [[congestive heart disease]] or [[hyperthyroidism]] preexist. Persons with [[hypertension]] may experience both exaggerated [[orthostatic hypotension]] and [[tachycardia]]. Similarly, [[autonomic neuropathy]] requires caution. Persons with a history of [[allergies]] or [[bronchial asthma]] will show a higher than normal incidence of [[hypersensitivity]] reactions. | ||
<!--Adverse Reactions--> | <!--Adverse Reactions--> | ||
<!--Clinical Trials Experience--> | <!--Clinical Trials Experience--> | ||
|clinicalTrials=*With nearly all antimuscarinic drugs, dry mouth is the first and dry skin is the second most common side effect. Thirst and difficulty in swallowing occur when the mouth and esophagus become sufficiently dry; chronic dry mouth also fosters dental caries. Suppression of sweating causes reflexive flushing and heat intolerance and can result in heat exhaustion or heat stroke in a hot environment; it also contributes to the hyperthermia seen in intoxication. Mydriasis frequently occurs, especially with scopolamine; photophobia and blurring of vision are consequences of mydriasis. Cycloplegia (which exacerbates blurred vision) occurs approximately concomitantly with mydriasis, but usually higher doses are required. In susceptible persons, especially the elderly, cycloplegia may contribute to an elevation of intraocular pressure. Difficulty in urination and urinary retention may occur. Tachycardia is a common side effect. Constipation, even bowel stasis, may occur. | |clinicalTrials=*With nearly all antimuscarinic drugs, dry mouth is the first and dry skin is the second most common side effect. Thirst and difficulty in swallowing occur when the mouth and esophagus become sufficiently dry; chronic dry mouth also fosters dental caries. Suppression of [[sweating]] causes reflexive [[flushing]] and [[heat intolerance]] and can result in [[heat exhaustion]] or [[heat stroke]] in a hot environment; it also contributes to the [[hyperthermia]] seen in intoxication. [[Mydriasis]] frequently occurs, especially with scopolamine; [[photophobia]] and blurring of vision are consequences of [[mydriasis]]. [[Cycloplegia]] (which exacerbates blurred vision) occurs approximately concomitantly with [[mydriasis]], but usually higher doses are required. In susceptible persons, especially the elderly, [[cycloplegia]] may contribute to an elevation of intraocular pressure. Difficulty in urination and urinary retention may occur. [[Tachycardia]] is a common side effect. [[Constipation]], even bowel stasis, may occur. | ||
*In the larger therapeutic doses, scopolamine may cause dizziness, restlessness, tremors, fatigue and locomotor difficulties. | *In the larger therapeutic doses, scopolamine may cause dizziness, restlessness, tremors, fatigue and locomotor difficulties. | ||
| Line 83: | Line 83: | ||
<!--Drug Interactions--> | <!--Drug Interactions--> | ||
|drugInteractions=*Other drugs, such as phenothiazines, tricyclic antidepressants, certain antihistamines, meperidine, etc., which have weak antimuscarinic activity, may considerably intensify the effects of antimuscarinic drugs. Aluminum- and magnesium trisilicate-containing antacids have been shown to decrease the absorption of some antimuscarinic drugs and may possibly do so with all of them.<!--Use in Specific Populations--> | |drugInteractions=*Other drugs, such as [[phenothiazines]], [[tricyclic antidepressants]], certain antihistamines, [[meperidine]], etc., which have weak antimuscarinic activity, may considerably intensify the effects of [[antimuscarinic]] drugs. Aluminum- and magnesium trisilicate-containing antacids have been shown to decrease the absorption of some antimuscarinic drugs and may possibly do so with all of them.<!--Use in Specific Populations--> | ||
|FDAPregCat=C | |FDAPregCat=C | ||
|useInPregnancyAUS=There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant. | |useInPregnancyAUS=There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant. | ||
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery. | |useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery. | ||
|useInNursing=*Problems in humans have not been documented; however, risk-benefit must be considered since barbiturates and belladonna alkaloids are excreted in breast milk. | |useInNursing=*Problems in humans have not been documented; however, risk-benefit must be considered since barbiturates and [[belladonna alkaloids]] are excreted in breast milk. | ||
|useInPed=*Safety and effectiveness in pediatric patients have not been established. | |useInPed=*Safety and effectiveness in pediatric patients have not been established. | ||
|useInGeri=*No overall differences in safety or effectiveness have been observed between elderly and younger patients. | |useInGeri=*No overall differences in safety or effectiveness have been observed between elderly and younger patients. | ||
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations. | |useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations. | ||
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations. | |useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations. | ||
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment. | |useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with [[renal impairment]]. | ||
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment. | |useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with [[hepatic impairment]]. | ||
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males. | |useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males. | ||
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised. | |useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are [[immunocompromised]]. | ||
<!--Administration and Monitoring--> | <!--Administration and Monitoring--> | ||
| Line 104: | Line 104: | ||
<!--Overdosage--> | <!--Overdosage--> | ||
|overdose=*Serious systemic intoxication can occur even from topical ophthalmologic application, especially in children, since both local absorption and nasolacrimal drainage into the gut can deliver considerable amounts to the circulation. In serious intoxication, hyperpyrexia, flushing, nausea, vomiting, drowsiness, disorientation, stupor, hallucinations, leukocytosis, nonallergenic rashes, circulatory or respiratory collapse, even death, in addition to all aforenamed effects, may occur. Children, especially infants and children with mongolism, spastic paralysis or brain damage, are more sensitive than adults to the toxic effects. | |overdose=*Serious systemic intoxication can occur even from topical ophthalmologic application, especially in children, since both local absorption and nasolacrimal drainage into the gut can deliver considerable amounts to the circulation. In serious intoxication, [[hyperpyrexia]], [[flushing]], [[nausea]], [[vomiting]], [[drowsiness]], disorientation, [[stupor]], [[hallucinations]], [[leukocytosis]], nonallergenic [[rashes]], circulatory or respiratory collapse, even death, in addition to all aforenamed effects, may occur. Children, especially infants and children with [[mongolism]], [[spastic paralysis]] or brain damage, are more sensitive than adults to the toxic effects. | ||
*If marked excitement is present and more specific treatment is not available, diazepam is most suitable for sedation and for control of convulsions. Large doses should be avoided because the central depressant action may coincide with the depression occurring late in belladonna poisoning. Phenothiazines should not be used because their antimuscuranic action is likely to intensify toxicity and may plunge the patient into coma. Artificial respiration with oxygen may be necessary. Ice bags and alcohol sponges help to reduce fever, especially in children. | *If marked excitement is present and more specific treatment is not available, [[diazepam]] is most suitable for sedation and for control of [[convulsions]]. Large doses should be avoided because the central depressant action may coincide with the [[depression]] occurring late in [[belladonna poisoning]]. [[Phenothiazines]] should not be used because their [[antimuscuranic]] action is likely to intensify toxicity and may plunge the patient into [[coma]]. Artificial respiration with [[oxygen]] may be necessary. Ice bags and alcohol sponges help to reduce [[fever]], especially in children. | ||
<!--Pharmacology--> | <!--Pharmacology--> | ||
| Line 175: | Line 175: | ||
|mechAction=*Scopolamine hydrobromide is one of the major antimuscarinic agents that inhibit the action of acetylcholine (ACh) on autonomic effectors innervated by postganglionic cholinergic nerves as well as on smooth muscles that lack cholinergic innervation. It exerts little effects on the actions of ACh at nicotinic receptor sites such as autonomic ganglia. The major action of this antimuscarinic agent is a surmountable antagonism to ACh and other muscarinic agents. | |mechAction=*Scopolamine hydrobromide is one of the major antimuscarinic agents that inhibit the action of acetylcholine (ACh) on autonomic effectors innervated by postganglionic cholinergic nerves as well as on smooth muscles that lack cholinergic innervation. It exerts little effects on the actions of ACh at nicotinic receptor sites such as autonomic ganglia. The major action of this antimuscarinic agent is a surmountable antagonism to ACh and other muscarinic agents. | ||
*As compared with atropine, scopolamine differs only quantitatively in antimuscarinic actions. Scopolamine has a stronger action on the iris, ciliary body and certain secretory glands such as salivary, bronchial and sweat. Scopolamine, in therapeutic doses, normally causes drowsiness, euphoria, amnesia, fatigue and dreamless sleep with a reduction in rapid-eye-movement sleep. However, the same doses occasionally cause excitement, restlessness, hallucinations or delirium, especially in the presence of severe pain. Scopolamine depresses the EEG arousal response to photostimulation. It is more potent than atropine on the antitremor activity (parkinsonism) in animals induced by surgical lesions. Scopolamine is effective in preventing motion sickness by acting on the maculae of the utricle and saccule. | *As compared with [[atropine]], scopolamine differs only quantitatively in antimuscarinic actions. Scopolamine has a stronger action on the [[iris]], [[ciliary body]] and certain secretory glands such as salivary, bronchial and sweat. Scopolamine, in therapeutic doses, normally causes [[drowsiness]], [[euphoria]], [[amnesia]], fatigue and dreamless sleep with a reduction in rapid-eye-movement sleep. However, the same doses occasionally cause excitement, restlessness, hallucinations or delirium, especially in the presence of severe pain. Scopolamine depresses the EEG arousal response to [[photostimulation]]. It is more potent than atropine on the antitremor activity ([[parkinsonism]]) in animals induced by surgical lesions. Scopolamine is effective in preventing [[motion sickness]] by acting on the [[maculae]] of the [[utricle]] and [[saccule]]. | ||
*Scopolamine, although less potent than atropine, has been used frequently in preanesthetic medication for the purpose of inhibiting the secretions of the nose, mouth, pharynx and bronchi and reduces the occurrence of laryngospasm during general anesthesia. Scopolamine is less potent in the decrease of cardiac rate, but not in the changes of blood pressure or cardiac output. Like other antimuscarinic agents, scopolamine has been used widely in the treatment of peptic ulcers and as an antispasmodic agent for G.I. disorders. This is due to the fact that scopolamine reduces salivary secretion, the gastric secretion (both the volume and acid content), and also it inhibits the motor activity of the stomach, duodenum, jejunum, ileum and colon, characterized by a decrease in tone, amplitude and frequency of peristaltic contractions. | *Scopolamine, although less potent than atropine, has been used frequently in preanesthetic medication for the purpose of inhibiting the secretions of the nose, mouth, pharynx and bronchi and reduces the occurrence of laryngospasm during general anesthesia. Scopolamine is less potent in the decrease of cardiac rate, but not in the changes of blood pressure or cardiac output. Like other [[antimuscarinic]] agents, scopolamine has been used widely in the treatment of peptic ulcers and as an antispasmodic agent for G.I. disorders. This is due to the fact that scopolamine reduces salivary secretion, the gastric secretion (both the volume and acid content), and also it inhibits the motor activity of the stomach, duodenum, jejunum, ileum and colon, characterized by a decrease in tone, amplitude and frequency of peristaltic contractions. | ||
<!--Structure--> | <!--Structure--> | ||
Revision as of 14:42, 8 May 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Scopolamine (injection) is an anticholinergic agent that is FDA approved for the treatment of central nervous system as a sedative and tranquilizing depressant and it is an effective antiemetic. Common adverse reactions include dry mouth, dizziness, somnolence, urinary retention, agitation, visual impairment, confusion, mydriasis and pharyngitis.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
- Scopolamine Hydrobromide Injection, USP is indicated as a sedative and tranquilizing depressant to the central nervous system. In its peripheral actions, scopolamine differs from atropine in that it is a stronger blocking agent for the iris, ciliary body and salivary, bronchial and sweat glands but is weaker in its action on the heart (in which it is incapable of exerting actions in tolerated doses), the intestinal tract and bronchial musculature.
- In addition to the usual uses for antimuscarinic drugs, scopolamine is employed for its central depressant actions as a sedative. Frequently it is given as a preanesthetic medicament for both its sedative-tranquilizing and antisecretory actions. It is an effective antiemetic. It is used in maniacal states, in delirium tremens and in obstetrics. As a mydriatic and cycloplegic, it has a somewhat shorter duration (3 to 7 days) and intraocular pressure is affected less markedly than with atropine.
Dosing Information
- For obstetric amnesia or preoperative sedation, 0.32 to 0.65 mg (320 to 650 mcg).
- For sedation or tranquilization, 0.6 mg (600 mcg) 3 or 4 times a day.
- Subcutaneous, as an antiemetic, 0.6 to 1 mg.
This image is provided by the National Library of Medicine.
03.png)
- Belladonna alkaloids provide a therapeutic effect in about 1 or 2 hours with a duration of about 4 hours.
- Geriatric and debilitated patients may respond to the usual doses with excitement, agitation, drowsiness or confusion; lower doses may be required in such patients.
- Close supervision is recommended for infants, blondes, mongoloids and children with spastic paralysis or brain damage, since an increased responsiveness to belladonna alkaloids has been reported in these patients and dosage adjustments are often required.
- Administration of belladonna alkaloids and barbiturates 30 to 60 minutes before meals is recommended to maximize absorption and, when issued for reducing stomach acid formation, to allow its effect to coincide better with antacid administration following the meal.
- Parenteral drug products should be inspected visually for particulate matter prior to administration, whenever solution and container permit.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Scopolamine (injection) in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Scopolamine (injection) in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
- Age 6 mo. to 3 yr., 0.1 to 0.15 mg (100 to 150 mcg). Age 3 to 6 yr., 0.2 to 0.3 mg (200 to 300 mcg).
- Subcutaneous, as antiemetic, 0.006 mg (6 mcg) per kg.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Scopolamine (injection) in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Scopolamine (injection) in pediatric patients.
Contraindications
- Scopolamine hydrobromide is contraindicated in patients with narrow-angle glaucoma, since administration of the drug could raise the intraocular pressure to dangerous levels. However, this will not happen for side-angle glaucoma patients. Repeated administration of scopolamine to a patient with chronic lung disease is considered to be potentially hazardous. Patients hypersensitive to belladonna or to barbiturates may be hypersensitive to scopolamine hydrobromide.
Warnings
- Addiction does not occur, although vomiting, malaise, sweating and salivation have been reported in patients with parkinsonism upon sudden withdrawal of large doses of scopolamine. Scopolamine is one of the most important drugs of the belladonna group from the standpoint of poisoning; infants and young children are especially susceptible to the belladonna alkaloids. Scopolamine is usually stated more toxic than atropine. Idiosyncrasy is more common with scopolamine than with atropine and ordinary therapeutic doses sometimes cause alarming reactions.
- FOR TOPICAL OPHTHALMIC USE ONLY - NOT FOR INJECTION.
Precautions
- If there is mydriasis and photophobia, dark glasses should be worn. Appropriate dosage precautions must be taken with infants, children, persons with mongolism, brain damage, spasticity, or light irides. Elevated intraocular pressure, urinary difficulty and retention and constipation are more probable in elderly persons. Men with prostatic hypertrophy should especially be monitored for urinary function. Because of the tachycardic effects of the drugs, care must be exercised when tachycardia, other tachyarrhythmias, coronary heart disease, congestive heart disease or hyperthyroidism preexist. Persons with hypertension may experience both exaggerated orthostatic hypotension and tachycardia. Similarly, autonomic neuropathy requires caution. Persons with a history of allergies or bronchial asthma will show a higher than normal incidence of hypersensitivity reactions.
Adverse Reactions
Clinical Trials Experience
- With nearly all antimuscarinic drugs, dry mouth is the first and dry skin is the second most common side effect. Thirst and difficulty in swallowing occur when the mouth and esophagus become sufficiently dry; chronic dry mouth also fosters dental caries. Suppression of sweating causes reflexive flushing and heat intolerance and can result in heat exhaustion or heat stroke in a hot environment; it also contributes to the hyperthermia seen in intoxication. Mydriasis frequently occurs, especially with scopolamine; photophobia and blurring of vision are consequences of mydriasis. Cycloplegia (which exacerbates blurred vision) occurs approximately concomitantly with mydriasis, but usually higher doses are required. In susceptible persons, especially the elderly, cycloplegia may contribute to an elevation of intraocular pressure. Difficulty in urination and urinary retention may occur. Tachycardia is a common side effect. Constipation, even bowel stasis, may occur.
- In the larger therapeutic doses, scopolamine may cause dizziness, restlessness, tremors, fatigue and locomotor difficulties.
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Scopolamine (injection) in the drug label.
Drug Interactions
- Other drugs, such as phenothiazines, tricyclic antidepressants, certain antihistamines, meperidine, etc., which have weak antimuscarinic activity, may considerably intensify the effects of antimuscarinic drugs. Aluminum- and magnesium trisilicate-containing antacids have been shown to decrease the absorption of some antimuscarinic drugs and may possibly do so with all of them.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA): C
There is no FDA guidance on usage of Scopolamine (injection) in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Scopolamine (injection) in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Scopolamine (injection) during labor and delivery.
Nursing Mothers
- Problems in humans have not been documented; however, risk-benefit must be considered since barbiturates and belladonna alkaloids are excreted in breast milk.
Pediatric Use
- Safety and effectiveness in pediatric patients have not been established.
Geriatic Use
- No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Gender
There is no FDA guidance on the use of Scopolamine (injection) with respect to specific gender populations.
Race
There is no FDA guidance on the use of Scopolamine (injection) with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Scopolamine (injection) in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Scopolamine (injection) in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Scopolamine (injection) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Scopolamine (injection) in patients who are immunocompromised.
Administration and Monitoring
Administration
Monitoring
- Barbiturates may increase Bromosulfonphthalein (BSP) levels; administration is not recommended during the 24 hours preceding the test.
IV Compatibility
There is limited information regarding IV Compatibility of Scopolamine (injection) in the drug label.
Overdosage
- Serious systemic intoxication can occur even from topical ophthalmologic application, especially in children, since both local absorption and nasolacrimal drainage into the gut can deliver considerable amounts to the circulation. In serious intoxication, hyperpyrexia, flushing, nausea, vomiting, drowsiness, disorientation, stupor, hallucinations, leukocytosis, nonallergenic rashes, circulatory or respiratory collapse, even death, in addition to all aforenamed effects, may occur. Children, especially infants and children with mongolism, spastic paralysis or brain damage, are more sensitive than adults to the toxic effects.
- If marked excitement is present and more specific treatment is not available, diazepam is most suitable for sedation and for control of convulsions. Large doses should be avoided because the central depressant action may coincide with the depression occurring late in belladonna poisoning. Phenothiazines should not be used because their antimuscuranic action is likely to intensify toxicity and may plunge the patient into coma. Artificial respiration with oxygen may be necessary. Ice bags and alcohol sponges help to reduce fever, especially in children.
Pharmacology
Mechanism of Action
- Scopolamine hydrobromide is one of the major antimuscarinic agents that inhibit the action of acetylcholine (ACh) on autonomic effectors innervated by postganglionic cholinergic nerves as well as on smooth muscles that lack cholinergic innervation. It exerts little effects on the actions of ACh at nicotinic receptor sites such as autonomic ganglia. The major action of this antimuscarinic agent is a surmountable antagonism to ACh and other muscarinic agents.
- As compared with atropine, scopolamine differs only quantitatively in antimuscarinic actions. Scopolamine has a stronger action on the iris, ciliary body and certain secretory glands such as salivary, bronchial and sweat. Scopolamine, in therapeutic doses, normally causes drowsiness, euphoria, amnesia, fatigue and dreamless sleep with a reduction in rapid-eye-movement sleep. However, the same doses occasionally cause excitement, restlessness, hallucinations or delirium, especially in the presence of severe pain. Scopolamine depresses the EEG arousal response to photostimulation. It is more potent than atropine on the antitremor activity (parkinsonism) in animals induced by surgical lesions. Scopolamine is effective in preventing motion sickness by acting on the maculae of the utricle and saccule.
- Scopolamine, although less potent than atropine, has been used frequently in preanesthetic medication for the purpose of inhibiting the secretions of the nose, mouth, pharynx and bronchi and reduces the occurrence of laryngospasm during general anesthesia. Scopolamine is less potent in the decrease of cardiac rate, but not in the changes of blood pressure or cardiac output. Like other antimuscarinic agents, scopolamine has been used widely in the treatment of peptic ulcers and as an antispasmodic agent for G.I. disorders. This is due to the fact that scopolamine reduces salivary secretion, the gastric secretion (both the volume and acid content), and also it inhibits the motor activity of the stomach, duodenum, jejunum, ileum and colon, characterized by a decrease in tone, amplitude and frequency of peristaltic contractions.
Structure
- Scopolamine Hydrobromide Injection, USP is a sterile solution of scopolamine hydrobromide (C17H21NO4 • HBr • 3H2O) in Water for Injection. The injection is preserved with methylparaben 0.18% and propylparaben 0.02%. Scopolamine Hydrobromide Injection is intended for intramuscular, intravenous and subcutaneous use. The pH (3.5-6.5) is adjusted with hydrobromic acid if necessary.
The structural formula is:
This image is provided by the National Library of Medicine.
01.png)
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Scopolamine (injection) in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Scopolamine (injection) in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Scopolamine (injection) in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Scopolamine (injection) in the drug label.
How Supplied
- Scopolamine Hydrobromide Injection, USP is supplied as:
This image is provided by the National Library of Medicine.
02.png)
- PROTECT FROM LIGHT.
- Use only if solution is clear and seal intact.
- Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Storage
There is limited information regarding Scopolamine (injection) Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Scopolamine (injection) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Scopolamine (injection) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Scopolamine (injection) in the drug label.
Precautions with Alcohol
- Alcohol-Scopolamine (injection) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- SCOPOLAMINE HYDROBROMIDE
Look-Alike Drug Names
There is limited information regarding Scopolamine (injection) Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ Putcha, L.; Cintrón, N. M.; Tsui, J.; Vanderploeg, J. M.; Kramer, W. G. (1989). "Pharmacokinetics and Oral Bioavailability of Scopolamine in Normal Subjects". Pharmacology Research. 6 (6): 481–485. doi:10.1023/A:1015916423156. PMID 2762223.
{{#subobject:
|Label Page=Scopolamine (injection) |Label Name=Scopolamine (injection)04.png
}}
{{#subobject:
|Label Page=Scopolamine (injection) |Label Name=Scopolamine (injection)05.png
}}
{{#subobject:
|Label Page=Scopolamine (injection) |Label Name=Scopolamine (injection)06.png
}}